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OBJECTIVE To evaluate the dose response relationship of moxonidine on plasma concentration of
norepinephrine during acute and chronic administration in patients with congestive heart
failure (CHF).
BACKGROUND Sympathetic activation is increased in heart failure. Moxonidine is an imidazoline ligand
acting on the central nervous system (CNS) receptors to decrease sympathetic activation.
METHODS Ninety-seven patients with heart failure and New York Heart Association class II–III
symptoms and ejection fraction ,40% were randomized to placebo or one of three target
doses of moxonidine, 0.1, 0.2 or 0.3 mg administered twice daily. An initial dose of
moxonidine 0.1 mg twice a day (b.i.d.) was followed by weekly increments of 0.1 mg b.i.d.
until target dose. The second and third study days occurred after four weeks (at target dose)
and after 12 weeks, respectively. At each study day, repeated blood samples were drawn.
RESULTS There was a significant dose-related decrease of systolic blood pressure across all three study
days. Heart rate decreased significantly on study day 3 in a dose-related manner. The acute
2 h decrease in plasma norepinephrine in response to all three doses of moxonidine was
significantly different compared with placebo after four and 12 weeks. There was a significant
linear relation between dose and plasma norepinephrine after four and 12 weeks in both 2 h
peak and the time averaged effect (.8 h). The number of adverse events was similar in the
moxonidine and placebo groups.
CONCLUSIONS The increased sympathetic activation in CHF can be reduced by moxonidine through CNS
inhibition. (J Am Coll Cardiol 2000;35:398–404) © 2000 by the American College of
Cardiology
Congestive heart failure (CHF) is associated with high
morbidity and mortality (1–3). The sympathetic nervous
system is activated (4) and is related to both the degree of
heart failure and to the prognosis (4–6). Pharmacological
therapy has been shown to decrease morbidity and mortality
mainly through inhibition of angiotensin converting en-
zyme (ACE) activity (1,2) or beta-adrenoreceptor antago-
nism (7–10). These therapies are both directed towards
counteracting neuroendocrine activation and the sympa-
thetic activation in particular. The efficacy of enalapril in
severe CHF is associated with a reduction of plasma
norepinephrine levels (5). Accordingly, the reduction of
sympathetic nervous system activity remains a primary
pathophysiological target both in patients with overt CHF
as well as those with asymptomatic left ventricular dysfunc-
tion (11).
As an alternative to blocking the peripheral effects of
norepinephrine, inhibiting central sympathetic outflow may
represent a useful means to interfere generally with the
adverse effects of elevated catecholamines on cardiac func-
tion (12). Agents acting on central sympathetic outflow,
such as the a2-agonist clonidine, have been studied in short
term intravenous and oral studies (13,14). Moxonidine is a
novel imidazoline ligand that acts specifically on central
nervous system (CNS) receptors to decrease sympathetic
nervous system tone (15). In preclinical studies, antihyper-
tensive effects appear to correlate with its potency at putative
brainstem imidazoline sites rather than to alpha2 receptors
(16). In clinical studies, moxonidine is an effective treatment
for hypertension and is equipotent to clonidine with fewer
alpha2-mediated side effects (17). The gastrointestinal ab-
sorption of moxonidine is rapid (t-max. 1 h after dosing)
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with elimination primarily via the urine. In postmarket
surveillance studies, moxonidine has been shown to be
well-tolerated; the most frequent side effects have included
dry mouth, dizziness and headache, all reported in ,3% in
hypertensive patients (18).
The pharmacodynamic effects of moxonidine in patients
with CHF are limited and, prior to this study, have only
been evaluated in an acute hemodynamic study including 10
patients (19). The aim of this study was to determine the
dose response relationship of oral moxonidine on plasma
concentration of norepinephrine during acute and chronic
administration in patients with symptomatic CHF. Addi-
tionally, tolerability was assessed with particular attention to
the incidence of symptomatic hypotension and effects on
vital signs.
METHODS
This was a double blind, placebo-controlled, multicenter
trial with a 12 week duration in patients with symptomatic
CHF in New York Heart Association (NYHA) functional
class II–III between 21 to 79 years of age. Thirteen centers
in Sweden and Norway participated (see Appendix). Pa-
tients with an ejection fraction ,40% assessed by radionu-
clide angiography, echocardiography or angiocardiography
treated with digitalis or diuretics were eligible. An ACE-
inhibitor was required if not contraindicated. The dosage of
all medication was stable for at least two weeks before
screening. Exclusion criteria included myocardial infarction
within the previous 90 days, significant valvular obstruction
or advanced pulmonary disease. Systolic blood pressure was
.90 mm Hg, and beta-adrenergic blocking agent use
within the previous three months was not allowed. The
protocol was approved by the ethics committee at each
participating center and each subject provided written in-
formed consent.
Protocol. After screening and baseline visits, patients were
randomly allocated to one of four treatment arms: tablets for
placebo or to target doses of moxonidine of 0.1, 0.2 or
0.3 mg administered b.i.d. All active medication started
with a dose of moxonidine of 0.1 mg twice daily followed by
weekly dose increments of 0.1 mg b.i.d. (or placebo if
needed) to the target dose. If side effects occurred, the dose
could be maintained, reduced or withdrawn. The first study
day was defined as the first of three separate days when
patients were observed for 8 h in the clinic for safety and
laboratory assessment. The second study day occurred after
four weeks of dosing at which time patients had reached the
target dose, if tolerated, and had maintained that dose for
two weeks. The third day was at the end of study after 12
weeks. At each study day, repeated blood samples were
drawn for assessment of plasma levels of norepinephrine
following 30 min of supine rest. Blood samples were drawn
before and 1, 2, 4 and 8 h after drug administration. Blood
was collected in vials containing glutathione. The plasmas
were placed on ice promptly and centrifuged for 20 min.
The plasmas were frozen, and they were shipped on dry ice
to a central laboratory where assay was performed by high
performance liquid chromatography (HPLC).
Possible effects of moxonidine on CNS function were
assessed by a questionnaire with specific questions aimed at
sedation (Solicited Sedation Events Questionnaire) (20,21).
Worsening heart failure and symptomatic hypotension were
evaluated by the clinical judgment of the investigators in the
absence of predefined criteria.
Statistics. The analyses included efficacy as well as safety
evaluations. The primary efficacy end point was the effect of
moxonidine on plasma norepinephrine. It was assessed by
linear regression of the change of plasma norepinephrine
from baseline to day 3 versus administered dose of mox-
onidine. The general linear model (GLM) compared dosage
groups versus placebo with dose as the independent variable
having a single degree of freedom, i.e., as a linear effect, and
the response variables as the dependent variables. The
models were fitted using the type III sums of squares option
in the GLM procedure (22). Least squares means were used
to summarize the results for each parameter.
Since the daily dosage of moxonidine was, in some cases,
lower than the dose to which a given patient was random-
ized, the dose used for the analyses described below was the
morning portion of the actual dose the patient received. The
baseline value of a variable was defined as the last measure-
ment obtained prior to the first administration of study drug
on Study Day 1 (placebo in 23 cases and 0.1 mg moxonidine
in the remaining cases). The predose values for Study Days
2 and 3 were defined as “0 h” values. The linear regression
model included fixed effects for dose, study site and the
interaction between dose and site. Each dose was also
compared with placebo. All tests of significance were
conducted at a two-sided alpha level of 0.05, except for
overall main effect on plasma norepinephrine level (one-
sided alpha level of 0.1).
The change from predose plasma norepinephrine concen-
tration to concentrations at 1, 2, 4 and 8 h after dosing was
analyzed in two ways: first, the acute effect of moxonidine
compared with placebo was evaluated as the change at 2 h
compared with predose values on Study Days 1, 2 and 3.
Second, the time-averaged values of plasma norepinephrine
over the 8 h interval after dosing were evaluated on Study
Abreviations and Acronyms
ACE 5 angiotensin converting enzyme
b.i.d. 5 twice a day
CHF 5 congestive heart failure
CNS 5 central nervous system
GLM 5 general linear model
HPLC 5 high performance liquid chromatography
NYHA 5 New York Heart Association
SD 5 standard deviation
SE 5 standard error of the mean
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Days 1, 2 and 3. The time-averaged effect was defined as the
area between the effect-time curve and the abscissa from
predose to the last measurement on the study day, divided
by the number of hours between the time of the predose
measurement and the last measurement.
Sample size was based on the following assumptions: the
average baseline level of plasma norepinephrine is 500
pg/ml 6 250 pg/ml [standard deviation (SD)]; a 25%
decrease is clinically significant; a one-sided significance
value of 0.1 and a power of 70%. Categorical variables were
compared for significance of association by chi-square anal-
ysis or Fisher’s exact test as indicated in Tables.
RESULTS
The patient demographics at baseline as originally random-
ized are presented in Table 1. There were 97 subjects with
an average age of 66 years. Angiotensin converting enzyme-
inhibitor therapy was used by 60% of the patients. Groups
were well-matched for most variables except baseline nor-
epinephrine (highest in the placebo group) and concomitant
ACE inhibitor use (lowest in the placebo group). The
maximal dose levels achieved are shown in Table 2. Six
patients could not reach the allocated dose level because of
hypotension. However, all such patients could be main-
tained on moxonidine at a lower dose level.
The effects of moxonidine on standing systolic blood
pressures and heart rate before and 2 h after drug intake on
each study day are presented in Figure 1. There was a
significant decrease of mean systolic blood pressure after the
first dose on Study Day 1 (all patients received 0.1 mg)
compared with placebo (p 5 0.0046); on Study Days 2 and
3, the effect on blood pressure was dose-related (p 5 0.0051
and 0.0001 for Study Days 2 and 3, respectively). Significant
falls to a similar extent in diastolic pressures were likewise
noted especially at the higher doses. The mean change in
standing heart rate 2 h after dose was not significant
compared with placebo for any dose on any of the three
study days. However, small (about 6 beats/min) but signif-
icant (p , 0.05) decreases in supine heart rate were noted
for the highest two doses on both Study Days 2 and 3
compared with placebo.
The mean plasma level of norepinephrine of the entire
study population at baseline according to randomized as-
signment for each group is shown in Table 1. The effects of
moxonidine on plasma norepinephrine are shown in Figure
2 and in Table 3. In the placebo group, there was a gradual
increase of trough plasma norepinephrine before the morn-
ing dose over the 12 week study period by approximately
25% (Fig. 2). In each of the moxonidine groups, the plasma
trough concentrations tended to be less on Study Days 2
and 3 compared with the placebo group, but these changes
did not reach significance. For example, there was a fall in
predose norepinephrine levels of 51 6 38 pg/ml (n 5 71)
and 78 6 25 pg/ml (n 5 69) in the combined moxonidine
groups compared with their respective placebo groups on
Study Day 2 (p 5 0.256) and Study Day 3 (p 5 0.284). On
the other hand, there was a clear reduction in plasma
norepinephrine levels in each drug group that was maximal
Table 1. Baseline Demographic Characteristics
Characteristics
Placebo
(n 5 23)
Moxonidine
0.2 mg
(n 5 24)
0.4 mg
(n 5 26)
0.6 mg
(n 5 24)
Male (%) 14 (61%) 19 (79%) 20 (77%) 20 (83%)
Age (yr) 67 66 65 65
Body weight (kg) 78 6 3 77 6 3 82 6 4 77 6 3
Ejection fraction (%) 28 6 5 27 6 2 29 6 1 28 6 1
NYHA class 2.5 6 0.1 2.7 6 0.1 2.6 6 0.1 2.4 6 0.1
Norepinephrine (pg/mL) 498 6 58 432 6 49 449 6 37 404 6 34
Median 410 347 400 361
Systolic pressure (mm Hg)* 119 6 5 121 6 4 115 6 4 121 6 5
Heart rate (beats/min)* 75 6 2 74 6 3 77 6 2 80 6 3
Patients on ACE inhibitors (%) 48 63 54 75
Unless otherwise specified, all continuous variables are expressed as mean (SEM).
ACE 5 angiotensin converting enzyme; NYHA 5 New York Heart Association.
*Standing values.
Table 2. Number of Patients Randomized to Each Drug Group
Compared With Final Dose Achieved
Placebo
Moxonidine
Group
(mg/day)
Total0.2 0.4 0.6
Total randomized 23 24 26 24 97
Maximal dose of moxonidine
achieved (mg/day)
0.2 24 1 2 27
0.4 — 25 3 28
0.6 — — 19 19
Values do not reflect deaths and discontinuations (see text).
400 Swedberg et al. JACC Vol. 35, No. 2, 2000
Moxonidine in Heart Failure February 2000:398–404
approximately 2 h following moxonidine administration
(Fig. 2 and Table 3). Plasma norepinephrine tended to
return progressively toward predose levels after the peak
effect. The acute responses to moxonidine (both peak effect
at 2 h and the time effect averaged over the 8 h postdosing
interval) were dose-related, and the linearized dose-effect
trend was significant on both Study Days 2 and 3 (Table 3).
The acute 2 h decrease in norepinephrine in response to all
three doses was significantly different compared with pla-
cebo on Study Day 3, while on Study Day 2, only the
response to the highest dose was significantly different from
placebo.
The percentage of patients with adverse effects in the
moxonidine and placebo groups were similar (74% in
placebo vs. 71%, 69% and 75% in moxonidine groups 0.2,
0.4 and 0.6 mg/day, respectively). The number of patients
who experienced worsening heart failure or died are dis-
played in Table 4. Three patients died, 1 patient in the
placebo group and 2 in the lowest moxonidine group. Seven
patients were judged clinically to have worsening heart
failure; 1 patient allocated to the highest moxonidine dosage
group (0.6 mg/day), 4 patients in the low dose group
(0.2 mg/day) and 2 patients in the placebo group. The
combination of worsening heart failure or death was in-
versely related to dose (p , 0.013, Fisher’s exact test).
Four patients discontinued therapy in the placebo group
as well as a total of six patients in the moxonidine groups (3,
1 and 2 in the 0.2, 0.4 and 0.6 mg/day groups, respectively).
Other than the three deaths (Table 4), the most common
reason for discontinuation was symptomatic hypotension
present in two subjects of the placebo group and one patient
each in the 0.4 and 0.6 mg/day moxonidine group. The
remaining three discontinuations were nonstudy related.
Symptomatic hypotension was recorded during the study in
a total of 30 patients. This symptom was more frequent in
patients receiving moxonidine (3 patients in the placebo
group and 6, 11 and 10 patients in the moxonidine 0.2, 0.4
and 0.6 mg/day group, respectively) (p , 0.015, by the
Mantel-Haenszel chi-square test). Other symptoms possi-
bly associated with hypotension were dizziness, vertigo and
syncope; all were more frequent in the moxonidine-treated
groups than in the placebo group, although dose-relatedness
was not strong. There were no significant sedative effects in
any group as assessed by the Solicited Events Sedation
questionnaire.
DISCUSSION
This study demonstrates a significant attenuation of plasma
norepinephrine concentrations by moxonidine in patients
Figure 1. Standing systolic pressures (top) and heart rate (bottom)
before and 2 h after moxonidine administration. All values are
mean 6 SE of 23 and 74 patients on Study Day 1 for placebo and
0.2 mg/day group, respectively. On the second study day, 21, 26,
27 and 19 patients were in the placebo, 0.2 mg, 0.4 mg and 0.6 mg
groups, respectively. On the third study day, 19, 23, 28 and 19
patients were in the placebo, 0.2 mg, 0.4 mg and 0.6 mg group,
respectively. Zero hours denote predose values on each study day.
Study Day 1, p 5 0.0046 vs. placebo. Study Day 2 and 3, difference
at 2 hours vs. placebo, p 5 0.005 and p 5 0.0001, respectively.
Figure 2. Plasma norepinephrine concentrations versus time as
normalized to initial baseline for each patient (value/baseline).
Baseline values (mean 6 SE) for patients who continued within
assigned group from baseline to Study Day 3 were: 485 pg/ml 6
54 (n 5 18), 464 pg/ml 6 52 (n 5 21), 441 pg/ml 6 31 (n 5 27)
and 387 pg/ml 6 39 (n 5 19) for placebo, 0.2 mg, 0.4 mg and
0.6 mg groups, respectively. Zero hours denote predose values for
each study day. Eight hour linearized dose-effect trend on Study
Day 2 and 3, p 5 0.03 and 0.0006, respectively.
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with CHF. This was accomplished with relatively few
adverse reactions. When symptomatic hypotensive reactions
did occur, they could be managed by lowering the dose of
moxonidine. Although a trend was evident, we could not
demonstrate a sustained reduction in predose plasma nor-
epinephrine over the course of the study in any group
compared with placebo. However, it is worth noting that
the decreases in plasma norepinephrine seen over the 8 h
after dosing observation period on each study day were
significant and sustained throughout the 12 weeks of dos-
ing.
Sympathetic activation and plasma norepinephrine.
Sympathetic activation can be assessed by measurement of
peripheral sympathetic nerve activity (23), myocardial nor-
epinephrine release (24) or plasma norepinephrine by pe-
ripheral blood sampling (4). Plasma norepinephrine reflects
sympathetic activation in CHF, but the actual contribution
of sympathetic cardiac activation is probably underestimated
(24). In patients not treated with ACE-inhibitors, plasma
norepinephrine concentrations are also related to the degree
of CHF (25), and the levels have prognostic implications
(4,5). Over time, plasma norepinephrine increases as heart
failure progresses (26,27).
The increase of plasma norepinephrine in the placebo
group over a 12 week period observed in this study is
somewhat more pronounced than previously reported in the
V-HeFT II and the SOLVD trial (6,26). There is evidence
that plasma norepinephrine concentration in patients with
CHF increases over time, presumably reflecting progression
of the underlying disease (26,27). For example, the average
plasma norepinephrine of both treatment groups in
V-HeFT II clearly trended higher at approximately parallel
rates of about 40 pg/ml per year over the 48 months of study
(26). In the SOLVD trials, the average baseline levels of
plasma norepinephrine were significantly higher in the
treatment group than they were in the prevention group (6),
reflecting the greater severity of failure.
The increase in plasma norepinephrine with time appears
Table 3. Acute Effects of Moxonidine on Plasma Norepinephrine Concentration*
Study Day/Dose† n‡
2 h Peak Effect
Change in
Norepinephrine
(pg/ml)
p¶
Value
Time Averaged Effect
Change in
Norepinephrine
(pg/ml)
p
Value
Study Day 1
Placebo 22 20.4 — 223.7 —
0.1 mg 71 243.4 0.25 237.1 0.65
Study Day 2
Placebo 20 211.7 — 218.3 —
0.1 mg 25 258.0 0.16 241.1 0.46
0.2 mg 27 252.9 0.20 224.3 0.84
0.3 mg 19 2125.5 0.001 295.5 0.016
Linear Trend\ 0.002 0.033
Study Day 3
Placebo 17 92.0 — 95.5 —
0.1 mg 23 242.2 0.017 223.0 0.036
0.2 mg 27 243.0 0.008 226.0 0.016
0.3 mg 19 286.0 0.0008 299.2 0.0003
Linear Trend\ 0.0015 0.0006
*Least square mean changes relative to predose plasma norepinephrine concentration on same day. †Dose administered on a
twice daily regimen. ‡N differs from number randomized due to dosage adjustments. Variation by study day results from
discontinuations and deaths. §For calculation of time averaged effect, refer to Methods section. \Linear trend of effect vs. dose,
refer to Methods section. ¶p values for each dose of moxonidine compared with placebo.
Table 4. Clinical Outcomes Worsening Heart Failure and Death
Allocation Group
Outcome
Placebo
(N 5 23)
Moxonidine
p Value
0.2 mg
(N 5 24)
0.4 mg
(N 5 26)
0.6 mg
(N 5 24)
Deaths 1 2 0 0
Worsening heart failure 3 1 1 2
Worsening heart failure or death 4 3 1 2 0.013
p value calculated by Fisher’s exact test.
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variable depending on the clinical status of the patients and
perhaps design features of various protocols. For example,
the patterns of temporal responses of the placebo and
enalapril treated groups differed between the SOLVD
treatment trial and the SOLVD prevention trial (6) point-
ing out the difficulty in comparing the time course of plasma
norepinephrine across trials when there are potentially
significant differences in the clinical status of the patients.
Moreover, the pretreatment drug regimens of the patients in
V-HeFT II and the SOLVD treatment trial did not include
ACE inhibitors (28), which were administered chronically
in the majority of the patients in this study. Selection of
patients on the basis of prior administration of ACE
inhibitors may have resulted in inclusion of patients later in
the chronological history of heart failure than would have
been true of patients of a similar NYHA class who were
studied before ACE inhibitors became standard therapy for
CHF. However, others have also observed large increases of
plasma norepinephrine over a time interval similar to ours.
In a comparison of low versus high doses of enalapril in
NYHA class III/IV heart failure, the respective increases in
plasma norepinephrine after 12 weeks of observation were
25% and 34% (27). The pretreatment plasma concentration
of both groups are close to the average value of the placebo
group in this study, suggesting similar severity of heart
failure, while the proportional increases in that study were
even greater than those in the placebo group seen in this
study.
Central inhibition of sympathetic activation. A small
group of neurons located in the rostroventrolateral reticular
nucleus possess both alpha2 and imidazoline (I1) receptive
sites (29,30). These vasomotor neurons project caudally
within the cord to excite preganglionic sympathetic neurons
probably by release of glutamate. The neurons play an
important role in regulating sympathetic outflow and, thus,
the systematic level of various neurohormones including
norepinephrine, renin and angiotensin (31). Several studies
suggest that moxonidine can specifically activate alpha2 (32)
or I1 receptors (33) located in this region of the CNS,
ultimately leading to decreased sympathetic outflow and
lowered blood pressure.
Clonidine was the first clinically available drug that
reduced sympathetic activation by central inhibition, and
short-term studies using clonidine in CHF have been
published (13,14). The acute beneficial hemodynamic ef-
fects and lower plasma norepinephrine in heart failure
patients are probably mediated by actions at both imidazo-
line and alpha2 receptive sites. However, clonidine has been
associated with moderate sedation and other nuisance side
effects that have limited its wider use. It has been proposed
that the alpha2 receptor agonist properties of clonidine
might be an important reason for this side effect (16,34).
The equivalent antihypertensive efficacy and lower side
effect profile of moxonidine compared with clonidine could
be explained by a 10–20 fold lower affinity than clonidine
for alpha2 receptors, while having nearly equal affinity for
purported type 1 imidazoline receptors in the rostrol-
ventrolateral medulla (15). In support of this, we could not
detect any significant sedative side effects of moxonidine in
this study.
Antiadrenergic therapies. Treatments that counteract the
increased neuroendocrine activation, and sympathetic acti-
vation in particular, have demonstrated beneficial effects on
morbidity and mortality in heart failure (1,2,8–10). An
intervention that modulates excessive sympathetic activation
by attenuation might, therefore, have important clinical
effects in patients with heart failure. In this regard, it is
worth noting that moxonidine recently has been shown to
reduce transmyocardial norepinephrine gradient as well as
total norepinephrine spillover in patients with moderate
CHF (35). Our findings of fewer events in the higher
moxonidine dose groups might suggest enhanced protection
from adverse cardiovascular events by reduced systemic and
cardiac adrenergic drive. This preliminary observation needs
confirmation in large prospective clinical trials.
The principal adverse effect associated with moxonidine
administration was symptomatic hypotension. This effect,
however, was transient and occurred at the time of peak
drug effect on blood pressure, heart rate and plasma nor-
epinephrine levels. The hypotensive reactions were manage-
able by dose adjustments. The occurrence of symptomatic
hypotension, in combination with the relatively short dura-
tion of the effect on plasma norepinephrine, has subse-
quently been addressed by modifying the dosage formula-
tion to yield enhanced tolerability and sustained plasma
norepinephrine reductions.
Conclusion. The increased sympathetic activation in CHF
can be reduced by the imidazoline ligand, moxonidine,
probably by acting on a population of adrenergic/
imidazoline receptive sites within the CNS. While the
findings from this study may be encouraging with regard to
the previously reported prognostic significance of elevated
plasma norepinephrine concentrations in patients with heart
failure, the potential clinical benefit of pharmacologically
targeting elevated plasma norepinephrine must be estab-
lished by controlled clinical trials with morbidity and
mortality as primary end points.
APPENDIX
The following study sites participated in the Moxonidine
Study: Norwegian Center: Rogaland Central Hospital: Ken-
neth Dickstein. Swedish Centers: Borås Hospital, Borås: C.
Wettervik; Danderyd Hospital, Danderyd: T. Kahan; Falun
Hospital, Falun: H. Saetre; Sahlgrenska University Hospi-
tal/Sahlgrenska, Go¨teborg: F. Waagstein and C-H. Bergh;
Sahlgrenska University Hospital/Mo¨lndal, Mo¨lndal: L.
Klintberg; Sahlgrenska University Hospital/O¨stra, Go¨te-
borg: M. Schaufelberger and K. Swedberg; Central Hospi-
tal, Karlstad: R. Karlsson; Linko¨ping University Hospital,
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Linko¨ping: U. Dahlstro¨m; Malmo¨ University Hospital,
Malmo¨: L. Erhardt and C. Cline; Norrko¨ping Hospital,
Norrko¨ping: O. Nilsson; Uddevalla Hospital, Uddevalla: B.
Karlson; Va¨sterås Central Hospital, Va¨sterås: G. Agert.
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